AB-005
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 895155-25-6 |
| Chemical data | |
| Formula | C23H32N2O |
| Molar mass | 352.51 g/mol |
AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.
Legal status
Psychoactive products in New Zealand containing this drug have been given interim approval under recent psychoactive substances legislation.[2]
See also
References
- ↑ Frost, J. M.; et al. (2010). "Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity". Journal of Medicinal Chemistry 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
- ↑ Ministry of Health – Manatū Hauora "Interim Product Approvals", Ministry of Health NZ, New Zealand, 2 January 2013. Retrieved on 2 January 2013.